Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Case Over Relacorilant

Overview

• - Multiple shareholder-rights firms are urging Corcept investors to seek lead-plaintiff status by April 21, 2026, a role that directs the case on the class's behalf.
• - The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics, No. 26-cv-01525, was filed in the U.S. District Court for the Northern District of California.
• - The complaint alleges Corcept told investors relacorilant was “approaching approval” and touted “powerful” trial results despite FDA feedback that its evidence, including the GRACE trial design, was not adequate.
• - The proposed class covers buyers of Corcept common stock from October 31, 2024 through December 30, 2025.
• - Notices emphasize that no class has been certified, so shareholders are not represented by class counsel unless they retain their own attorney.